HomeCRSP • NASDAQ
Crispr Therapeutics AG
$70.16
After Hours:
$70.00
(0.23%)-0.16
Closed: Mar 27, 7:29:46 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed securityCH headquartered
Previous close
$70.97
Day range
$68.88 - $71.54
Year range
$37.55 - $91.10
Market cap
5.63B USD
Avg Volume
1.98M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
201.21M3,353,333.33%
Operating expense
16.48M-22.16%
Net income
89.35M180.80%
Net profit margin
44.41100.00%
Earnings per share
1.10178.01%
EBITDA
74.48M159.26%
Effective tax rate
0.26%
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
1.69B-6.70%
Total assets
2.23B-0.60%
Total liabilities
346.77M-5.66%
Total equity
1.88B
Shares outstanding
80.28M
Price to book
3.02
Return on assets
8.06%
Return on capital
8.50%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
89.35M180.80%
Cash from operations
-96.07M15.23%
Cash from investing
-81.45M53.60%
Cash from financing
38.94M1,471.39%
Net change in cash
-138.53M51.61%
Free cash flow
-130.62M-37.38%
About
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Founded
2013
Employees
407
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu